LNCR
MCID: LNG032
MIFTS: 99

Lung Cancer (LNCR)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 57 12 76 25 75 29 6 43 3 15
Non-Small Cell Lung Cancer 76 37 29 6
Lung Cancer, Protection Against 57 29 6
Lung Carcinoma 12 55 15
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 57 13
Nonsmall Cell Lung Cancer, Somatic 57 13
Lung Cancer, Susceptibility to 57 6
Non-Small Cell Lung Carcinoma 38 73
Malignant Neoplasm of Lung 25 73
Nonsmall Cell Lung Cancer 57 75
Alveolar Cell Carcinoma 75 29
Carcinoma of Lung 12 73
Lung Neoplasms 25 73
Lung Neoplasm 12 76
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 57
Nonsmall Cell Lung Cancer, Susceptibility to 57
Primary Malignant Neoplasm of Lung 73
Bronchioloalveolar Adenocarcinoma 73
Adenocarcinoma of Lung, Somatic 57
Carcinoma Non-Small Cell Lung 55
Cancer, Lung, Non-Small Cell 40
Lung Cancer, Resistance to 57
Malignant Tumor of Lung 25
Adenocarcinoma of Lung 75
Lung Malignant Tumors 25
Respiratory Carcinoma 25
Lung Cancer, Somatic 57
Malignant Lung Tumor 25
Pulmonary Carcinoma 25
Pulmonary Neoplasms 25
Cancer of Bronchus 25
Cancer of the Lung 25
Lung Malignancies 25
Pulmonary Cancer 25
Neoplasm of Lung 29
Cancer of Lung 12
Cancer, Lung 40
Cancer Lung 55
Lncr 75

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
lung cancer:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lung Cancer

MedlinePlus : 43 Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk. Common symptoms of lung cancer include A cough that doesn't go away and gets worse over time Constant chest pain Coughing up blood Shortness of breath, wheezing, or hoarseness Repeated problems with pneumonia or bronchitis Swelling of the neck and face Loss of appetite or weight loss Fatigue Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Lung Cancer, also known as non-small cell lung cancer, is related to lung cancer susceptibility 3 and adenosquamous lung carcinoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are alveolar cell carcinoma and Decreased viability

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

Genetics Home Reference : 25 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

OMIM : 57 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

CDC : 3 CDC works with partners to reduce the burden of lung cancer in the United States. Learn what CDC is doing.

UniProtKB/Swiss-Prot : 75 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia : 76 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Benign Neoplasm Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 988)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 35.2 AKT1 ALK BRAF CASP8 EGFR ERBB2
2 adenosquamous lung carcinoma 34.6 ALK EGFR ERBB2 KRAS PIK3CA
3 small cell cancer of the lung 34.6 AKT1 EGFR KIT PIK3CA PTEN
4 lung adenoid cystic carcinoma 33.3 PIK3CA KRAS KIT ALK
5 lung squamous cell carcinoma 33.2 AKT1 ALK BRAF EGFR KRAS PIK3CA
6 adenocarcinoma 32.3 AKT1 ALK BRAF EGFR ERBB2 KIT
7 breast cancer 31.9 AKT1 ALK BRAF CASP8 EGFR ERBB2
8 colorectal cancer 31.8 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
9 squamous cell carcinoma 31.7 AKT1 BRAF EGFR ERBB2 PIK3CA PTEN
10 ovarian cancer 31.4 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
11 esophageal cancer 31.2 AKT1 CASP8 EGFR ERBB2 FASLG KRAS
12 glioblastoma 31.2 AKT1 ALK BRAF EGFR ERBB2 NRAS
13 neuroblastoma 31.2 AKT1 ALK CASP8 KIT NRAS PIK3CA
14 gastric cancer 31.1 AKT1 EGFR ERBB2 IRF1 KRAS PIK3CA
15 prostate cancer 31.1 AKT1 CASP8 EGFR ERBB2 KRAS MAP2K1
16 hepatocellular carcinoma 31.1 AKT1 CASP8 EGFR FASLG KRAS MAP2K1
17 small cell carcinoma 31.0 EGFR KIT PTEN
18 thyroid cancer 31.0 AKT1 BRAF EGFR KIT KRAS MAP2K1
19 gastric adenocarcinoma 31.0 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
20 myeloma, multiple 31.0 AKT1 BRAF CASP8 KIT KRAS NRAS
21 glioma 30.9 BRAF EGFR ERBB2 PIK3CA PTEN
22 adenosquamous carcinoma 30.8 EGFR KIT KRAS PIK3CA
23 pancreatic cancer 30.7 AKT1 EGFR ERBB2 KRAS MAP2K1 PIK3CA
24 gastrointestinal stromal tumor 30.7 AKT1 BRAF EGFR KIT KRAS PTEN
25 adenoid cystic carcinoma 30.7 AKT1 ERBB2 KIT KRAS PIK3CA PTEN
26 squamous cell carcinoma, head and neck 30.7 AKT1 BRAF EGFR ERBB2 PIK3CA PTEN
27 carcinosarcoma 30.6 ERBB2 KIT KRAS PIK3CA PTEN
28 breast adenocarcinoma 30.6 AKT1 CASP8 EGFR ERBB2 KRAS PIK3CA
29 glioblastoma multiforme 30.6 AKT1 EGFR ERBB2 PIK3CA PTEN
30 leukemia, acute myeloid 30.6 AKT1 CASP8 KIT KRAS NRAS
31 adamantinoma of long bones 30.5 BRAF CASP8 EGFR ERBB2 KRAS PIK3CA
32 bladder urothelial carcinoma 30.5 AKT1 BRAF ERBB2 KRAS MAP2K1 NRAS
33 transitional cell carcinoma 30.5 BRAF EGFR ERBB2 PTEN
34 suppression of tumorigenicity 12 30.5 AKT1 BRAF PIK3CA PTEN
35 cervical cancer 30.5 AKT1 CASP8 ERBB2 IRF1 PIK3CA PPP2R1B
36 lymphoproliferative syndrome 30.4 CASP8 FASLG NRAS
37 langerhans cell histiocytosis 30.4 BRAF MAP2K1 NRAS
38 uterine carcinosarcoma 30.4 EGFR ERBB2 KIT PIK3CA PTEN
39 gallbladder cancer 30.4 AKT1 EGFR ERBB2 KRAS PIK3CA
40 leukemia, chronic lymphocytic 2 30.4 BRAF KRAS NRAS
41 lymphoma, non-hodgkin, familial 30.4 ALK BRAF CASP8 NRAS PIK3CA
42 ovarian cancer 1 30.3 AKT1 ERBB2 KRAS PIK3CA
43 estrogen-receptor positive breast cancer 30.3 AKT1 EGFR ERBB2 PIK3CA
44 undifferentiated pleomorphic sarcoma 30.2 KIT KRAS PIK3CA
45 mucinous adenocarcinoma 30.2 ALK EGFR KRAS
46 ovary adenocarcinoma 30.2 ERBB2 KRAS PIK3CA
47 colorectal adenocarcinoma 30.1 BRAF EGFR KRAS
48 testicular germ cell tumor 30.1 BRAF KIT PTEN
49 paronychia 29.9 EGFR KRAS
50 lung cancer susceptibility 1 12.5

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Symptoms via clinical synopsis from OMIM:

57
Lung:
alveolar cell carcinoma
non-small-cell cancer


Clinical features from OMIM:

211980

Human phenotypes related to Lung Cancer:

32
# Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 32 HP:0006519

UMLS symptoms related to Lung Cancer:


fever, dyspnea, hemoptysis, snoring, coughing

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 92)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.22 BRAF KRAS EGFR PIK3CA
2 Decreased viability GR00106-A-0 11.22 KRAS
3 Decreased viability GR00107-A-1 11.22 MAP2K1
4 Decreased viability GR00221-A-1 11.22 KIT KRAS EGFR PIK3CA AKT1 NRAS
5 Decreased viability GR00221-A-2 11.22 KRAS MAP3K8 PIK3CA AKT1
6 Decreased viability GR00221-A-3 11.22 MAP3K8 AKT1 ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 11.22 BRAF MAP3K8 EGFR PIK3CA AKT1 ERBB2
8 Decreased viability GR00301-A 11.22 BRAF KIT KRAS MAP3K8
9 Decreased viability GR00342-S-1 11.22 MAP3K8 MAP2K1
10 Decreased viability GR00342-S-2 11.22 MAP3K8 MAP2K1
11 Decreased viability GR00342-S-3 11.22 MAP3K8 MAP2K1
12 Decreased viability GR00381-A-1 11.22 BRAF KRAS
13 Decreased viability GR00402-S-2 11.22 BRAF KIT KRAS MAP3K8 EGFR PIK3CA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.8 PRKN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.8 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.8 CYP2A6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.8 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.8 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.8 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.8 KRAS
21 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.8 EGFR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.8 IRF1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.8 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.8 IRF1 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.8 PIK3CA KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.8 IRF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.8 AKT1 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.8 ERBB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.8 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.8 BRAF PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.8 KRAS ERBB2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.8 KIT PRKN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.8 CYP2A6
34 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.8 AKT1 BRAF CYP2A6 KRAS PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.8 PIK3CA EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.8 BRAF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.8 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.8 PRKN
39 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.8 PRKN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.8 ERBB2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.8 EGFR
42 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.8 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.8 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.8 BRAF IRF1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.8 KIT
46 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.8 BRAF
47 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.8 BRAF ERBB2 IRF1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.8 CYP2A6 PRKN
49 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.8 AKT1 PIK3CA KIT
50 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.8 CYP2A6 EGFR

MGI Mouse Phenotypes related to Lung Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
2 cardiovascular system MP:0005385 10.5 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
3 homeostasis/metabolism MP:0005376 10.49 AKT1 ALK BRAF CASP8 EGFR ERBB2
4 growth/size/body region MP:0005378 10.46 AKT1 ALK BRAF CASP8 EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.44 AKT1 ALK BRAF CASP8 EGFR ERBB2
6 integument MP:0010771 10.44 AKT1 ALK BRAF CASP8 EGFR ERBB2
7 mortality/aging MP:0010768 10.42 AKT1 ALK BRAF CASP8 EGFR ERBB2
8 immune system MP:0005387 10.39 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
9 hematopoietic system MP:0005397 10.38 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
10 behavior/neurological MP:0005386 10.37 AKT1 ALK BRAF ERBB2 ERCC6 KIT
11 neoplasm MP:0002006 10.36 AKT1 ALK BRAF CASP8 EGFR ERBB2
12 embryo MP:0005380 10.34 AKT1 BRAF CASP8 EGFR ERBB2 KIT
13 nervous system MP:0003631 10.31 AKT1 ALK BRAF CASP8 EGFR ERBB2
14 digestive/alimentary MP:0005381 10.3 BRAF EGFR ERBB2 FASLG KIT KRAS
15 muscle MP:0005369 10.22 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
16 liver/biliary system MP:0005370 10.21 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
17 normal MP:0002873 10.18 AKT1 BRAF EGFR ERBB2 FASLG IRF1
18 craniofacial MP:0005382 10.16 BRAF EGFR ERBB2 KIT KRAS MAP2K1
19 limbs/digits/tail MP:0005371 10.13 BRAF EGFR ERBB2 ERCC6 KIT KRAS
20 hearing/vestibular/ear MP:0005377 10.05 BRAF EGFR ERCC6 KIT KRAS MAP2K1
21 reproductive system MP:0005389 10.03 AKT1 ALK BRAF EGFR ERBB2 FASLG
22 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG IRF1 KIT
23 pigmentation MP:0001186 9.91 ALK BRAF EGFR KIT KRAS NRAS
24 respiratory system MP:0005388 9.9 AKT1 ALK BRAF CASP8 EGFR ERBB2
25 skeleton MP:0005390 9.83 AKT1 ALK BRAF EGFR ERBB2 ERCC6
26 vision/eye MP:0005391 9.36 ALK BRAF EGFR ERCC6 FASLG KIT

Drugs & Therapeutics for Lung Cancer

FDA approved drugs:

(show all 23)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
3
Avastin 18 49 BEVACIZUMAB Genentech July 2009
4
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
5
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
6
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
7
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
8
Iressa 18 49 GEFITINIB AstraZeneca May 2003
9
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
10
Neutroval 18 tbo-filgrastim Teva Pharmaceutical August 2012
11
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
12
Photodynamic Therapy (& Photofrin) 18 PORFIMER SODIUM Sanofi-aventis January, 1996
13
Photofrin 18 PORFIMER SODIUM QLT January 1998
14
Quadramet 18 SAMARIUM SM-153 LEXIDRONAM PENTASODIUM DuPont Merck Pharmaceutical Company March 1997
15
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
16
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
17
Xalkori 18 49 CRIZOTINIB Pfizer August of 2011
18
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
19
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zykadia 18 49 CERITINIB Novartis April 2014
21
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015
22
Portazza 18 NECITUMUMAB Eli Lilly November 2015
23
Tagrisso 18 OSIMERTINIB MESYLATE AstraZeneca November 2015

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 990)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terbutaline Approved Phase 4 23031-25-6 5403
2
Ipratropium Approved Phase 4,Not Applicable 60205-81-4, 22254-24-6 43232
3
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
4
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
5
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
7
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
9
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
11
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
12
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
13
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
14
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
15
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
16
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
17
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
18
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
19
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
22
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
23
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
24
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71486-22-1 60780 44424639
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 437-38-7 3345
26
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
27
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
28
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
30
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
31
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
32
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
33
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
34
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95734-82-0
35
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 175805 71273
36
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
37 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
39
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20537-88-6 2141
40
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
41
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable 616-91-1 12035
42
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
43
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
44
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
45
Ondansetron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
46
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 6918365 151165
47
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
48
Nabilone Approved, Investigational Phase 4,Phase 2,Phase 3 51022-71-0 5284592
49
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
50
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 7138)
# Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
4 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
5 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
6 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
7 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
8 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
9 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
10 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
13 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
14 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
15 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
16 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
17 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
18 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
19 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
20 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
21 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
22 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
23 Effects of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction in Patients With Lung Cancer Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
24 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
25 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
26 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4 fentanyl matrix
27 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
28 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
29 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
30 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
31 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
32 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
33 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
34 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
35 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
36 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
37 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
38 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
39 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
40 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
41 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
42 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
43 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
44 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
45 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
46 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
47 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
48 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
49 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
50 Bio-behavioral Lung Cancer Prevention Program Completed NCT00322205 Phase 4 zyban

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
2 Lung Cancer 29 BRAF CASP8 CYP2A6 DLEC1 EGFR ERBB2 ERCC6 FASLG IRF1 KRAS MAP3K8 PIK3CA PPP2R1B PRKN RASSF1 SLC22A18
3 Lung Cancer, Protection Against 29
4 Neoplasm of Lung 29
5 Alveolar Cell Carcinoma 29

Anatomical Context for Lung Cancer

MalaCards organs/tissues related to Lung Cancer:

41
Lung, Brain, Breast, Testes, Lymph Node, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

19
The Lung

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 21949)
# Title Authors Year
1
SPECT V/Q in Lung Cancer Radiotherapy Planning. ( 30545514 )
2019
2
Interprofessional Perspectives on Providing Spiritual Care for Patients With Lung Cancer in Outpatient Settings. ( 30547964 )
2019
3
Palbociclib overcomes afatinib resistance in non-small cell lung cancer. ( 30551429 )
2019
4
Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer. ( 30551440 )
2019
5
LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway. ( 30551520 )
2019
6
Systems pharmacology uncover the mechanism of anti-non-small cell lung cancer for Hedyotis diffusa Willd. ( 30551551 )
2019
7
Long non-coding RNA DLEU1 exerts an oncogenic function in non-small cell lung cancer. ( 30551552 )
2019
8
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. ( 30528799 )
2019
9
Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells. ( 30502651 )
2019
10
NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer. ( 30508513 )
2019
11
Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer. ( 30481147 )
2019
12
A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. ( 30482524 )
2019
13
Long Non-Coding RNA Brain Cytoplasmic RNA 1 Acts as an Oncogene and Regulates Cell Proliferation and Metastasis in Non-Small Cell Lung Cancer. ( 30486938 )
2019
14
Role of immunotherapy in stage III nonsmall cell lung cancer. ( 30489337 )
2019
15
Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? ( 30451714 )
2019
16
Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer. ( 30431074 )
2019
17
DOK7V1 influences the malignant phenotype of lung cancer cells through PI3K/AKT/mTOR and FAK/paxillin signaling pathways. ( 30431081 )
2019
18
EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis. ( 30431083 )
2019
19
Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. ( 30418192 )
2019
20
Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-β and TRAIL and suppress the growth of H460 human lung cancer cells. ( 30393160 )
2019
21
Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. ( 30394941 )
2019
22
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer. ( 30407231 )
2019
23
Lysosome Membrane Permeabilization and Disruption of the Molecular Target of Rapamycin (mTOR)-Lysosome Interaction Are Associated with the Inhibition of Lung Cancer Cell Proliferation by a Chloroquinoline Analog. ( 30409790 )
2019
24
Socioeconomic deprivation and inequalities in lung cancer: time to delve deeper? ( 30381398 )
2019
25
LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy. ( 30387831 )
2019
26
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. ( 30387848 )
2019
27
MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer. ( 30365049 )
2019
28
Suppression of cyclooxygenase 2 increases chemosensitivity to sesamin through the Akt‑PI3K signaling pathway in lung cancer cells. ( 30365050 )
2019
29
Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer. ( 30365094 )
2019
30
Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation. ( 30365122 )
2019
31
Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT. ( 30365151 )
2019
32
The chemopreventive isothiocyanate sulforaphane reduces anoikis resistance and anchorage-independent growth in non-small cell human lung cancer cells. ( 30365975 )
2019
33
Prognostic and Added Value of Echocardiographic Strain for Prediction of Adverse Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer after Radiotherapy. ( 30366608 )
2019
34
Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. ( 30347283 )
2019
35
Preoperative albumin-to-globulin ratio predicts survival in patients with non-small-cell lung cancer after surgery. ( 30317549 )
2019
36
Phosphorylation of nucleolin is indispensable to its involvement in the proliferation and migration of non-small cell lung cancer cells. ( 30320343 )
2019
37
Increased expression of long non-coding RNA SNHG16 correlates with tumor progression and poor prognosis in non-small cell lung cancer. ( 30287374 )
2019
38
Bisphenol S (BPS) triggers the migration of human non-small cell lung cancer cells via upregulation of TGF-β. ( 30292839 )
2019
39
A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. ( 30229527 )
2019
40
CCDC85B promotes non-small cell lung cancer cell proliferation and invasion. ( 30242906 )
2019
41
Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines. ( 30243827 )
2019
42
Metabolomic study of serum, urine and bronchoalveolar lavage fluid based on gas chromatography mass spectrometry to delve into the pathology of lung cancer. ( 30292984 )
2019
43
Characterization of germline mutations in familial lung cancer from the Chinese population. ( 29054765 )
2018
44
Lipid-poor adrenal adenoma versus metastasis in lung cancer: Diagnosis by "comparative enhancement" at multiphasic MR imaging. ( 29970786 )
2018
45
Downregulation of CD24 suppresses bone metastasis of lung cancer. ( 29095550 )
2018
46
RAGE may act as a tumour suppressor to regulate lung cancer development. ( 29421442 )
2018
47
The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies. ( 29164315 )
2018
48
Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes. ( 29556585 )
2018
49
Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer. ( 29353659 )
2018
50
Lung Cancer Mortality in Tuscany from 1971 to 2010 and Its Connections with Silicosis: A Space-Cohort Analysis Based on Shared Models. ( 29796059 )
2018